Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

52.62 +1.02 (+1.98%)

Streaming Delayed Price Updated: 12:19 PM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

44 45 Next >

Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison ↗

September 18, 2023

Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...

Via Benzinga

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival ↗

September 18, 2023

Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.

Via Investor's Business Daily

One Year Into Kabir Nath's Leadership, Compass Pathways' (NASDAQ: CMPS) Phase 3 Trial For Innovative Treatment Resistant Depression Progressing ↗

September 18, 2023

Treatment-resistant depression, also referred to as TRD, is a subset of depression that poses significant challenges for clinicians, patients and those closest to patients. It is characterized by...

Via Benzinga

Pleasant Surprise For GSK: FDA Approves Bone Marrow Cancer Therapy Acquired Via Sierra Oncology Deal ↗

September 18, 2023

FDA has

Via Benzinga

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia

September 15, 2023

From GSK plc

Via Business Wire

Peering Into GSK's Recent Short Interest ↗

August 29, 2023

Via Benzinga

Looking Into GSK's Recent Short Interest ↗

August 04, 2023

Via Benzinga

Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs ↗

September 14, 2023

On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics,

Via Benzinga

Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm ↗

September 13, 2023

Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony.

Via InvestorPlace

Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood' ↗

September 13, 2023

Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite.

Via Investor's Business Daily

FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch ↗

September 12, 2023

According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for...

Via Benzinga

A Look Into GSK Inc's Price Over Earnings ↗

August 03, 2023

Via Benzinga

Is GSK Stock Worth Buying Right Now? ↗

July 29, 2023

GSK stock could be a bargain.

Via The Motley Fool

3 Pharmaceutical Stocks That Are Too Cheap to Ignore ↗

September 09, 2023

Viatris, GSK, and Organon are all trading at less than 7 times earnings.

Via The Motley Fool

GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

September 05, 2023

From GSK plc

Via Business Wire

Vivek Ramaswamy's Parallels With Warren Buffett Run Deeper Than Wanting To Make Roivant The 'Berkshire Hathaway Of Drug Development' ↗

September 04, 2023

Presidential hopeful Vivek Ramaswamy and Warren Buffett may share different political ideologies but they have at least a couple of things in common.

Via Benzinga

7 Stocks Hedge Funds Are Loading Up On ↗

September 03, 2023

Hedge funds and many other financial institutions are loading up on these names considered to be among top institutional stock picks.

Via InvestorPlace

GSK To Invest $272M In New Vaccine Facility Near Brussels, Slated To Open In 2027 ↗

August 30, 2023

GSK Plc (NYSE: GSK) has made an investment of over €250 million ($272 million) in a vaccine facility located in Belgium.

Via Benzinga

3 Growth Stocks to Ride the Coming Bull Market in Style ↗

August 26, 2023

Bull markets always follow bear markets, and these three companies are growth stocks to buy for the next wave higher

Via InvestorPlace

3 Sorry Pharma Stocks to Sell in August Before It’s Too Late ↗

August 22, 2023

Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell.

Via InvestorPlace

FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth ↗

August 22, 2023

Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth...

Via Benzinga

GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies

August 17, 2023

From GSK plc

Via Business Wire

Is GSK an Excellent Dividend Stock to Buy for Passive Income Investors? ↗

August 14, 2023

GSK offers a robust dividend yield, but that's not the only thing to consider.

Via The Motley Fool

3 Pharma Stocks to Sell in August Before They Crash and Burn ↗

August 11, 2023

Stay far away from these pharma stocks that are suffering from declining sales and weak pipelines of future products.

Via InvestorPlace

GSK, Pfizer Lock Horns Over Patent Fight Related To Respiratory Syncytial Virus Vaccine ↗

August 02, 2023

GSK Plc (NYSE: GSK) has sued Pfizer Inc (NYSE: PFE) in Delaware court, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's four patent rights in its RSV

Via Benzinga

GSK's Jemperli Plus Chemo Combo Scores FDA Approval As First New Frontline Treatment For Certain Type Of Endometrial Cancer ↗

August 01, 2023

The FDA approved GSK plc's (NYSE: GSK) Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for primary advanced or recurrent endometrial cancer...

Via Benzinga

Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer

July 31, 2023

From GSK plc

Via Business Wire

If You Can Only Buy One Dividend Stock, It Better Be One of These 7 Names ↗

July 30, 2023

Here are seven of the best dividend stocks to consider immediately. Better, each of these stocks have strong, stable businesses.

Via InvestorPlace

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes ↗

July 30, 2023

Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.

Via InvestorPlace

GSK Says 'Excellent' Q2 Performance Boosted By Vaccine & HIV Drug Sales, Raises 2023 Outlook ↗

July 26, 2023

GSK plc (NYSE: GSK) reported Q2 FY23 sales of £7.18 billion ($8.97 billion), up 4% Y/Y on t

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.